Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 2, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.62 to $7,318,309.60.

Highlighted Stocks Traded by Insiders:

HSN (HSNI) - FREE Research Report

Brand William C, who is President, HSN at HSN, sold 3,000 shares at $70.47 on July 2, 2015. Following this transaction, the President, HSN owned 31,203 shares meaning that the stake was reduced by 8.77% with the 3,000-share transaction.

The shares most recently traded at $70.19, down $0.28, or 0.4% since the insider transaction. Historical insider transactions for HSN go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 23,000

The average volume for HSN has been 272,000 shares per day over the past 30 days. HSN has a market cap of $3.7 billion and is part of the services sector and specialty retail industry. Shares are down 7.36% year-to-date as of the close of trading on Wednesday.

HSN, Inc. operates as an interactive multi-channel retailer in the United States. It operates through two segments, HSN and Cornerstone. The stock currently has a dividend yield of 1.99%. The company has a P/E ratio of 21.3. Currently, there are 6 analysts who rate HSN a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HSNI - FREE

TheStreet Quant Ratings rates HSN as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and notable return on equity. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full HSN Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AMAG Pharmaceuticals (AMAG) - FREE Research Report

Heiden William K, who is Ceo at AMAG Pharmaceuticals, sold 2,000 shares at $69.41 on July 2, 2015. Following this transaction, the Ceo owned 206,721 shares meaning that the stake was reduced by 0.96% with the 2,000-share transaction.

The shares most recently traded at $70.47, up $1.06, or 1.5% since the insider transaction. Historical insider transactions for AMAG Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,221
  • 12-Week # shares sold: 56,125
  • 24-Week # shares sold: 56,125

The average volume for AMAG Pharmaceuticals has been 750,400 shares per day over the past 30 days. AMAG Pharmaceuticals has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 65.88% year-to-date as of the close of trading on Wednesday.

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. The company has a P/E ratio of 11.2. Currently, there are 4 analysts who rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMAG - FREE

TheStreet Quant Ratings rates AMAG Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full AMAG Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ciena (CIEN) - FREE Research Report

Moylan James E Jr, who is SVP Finance, CFO at Ciena, sold 1,000 shares at $24.20 on July 2, 2015. Following this transaction, the SVP Finance, CFO owned 391,227 shares meaning that the stake was reduced by 0.25% with the 1,000-share transaction.

The shares most recently traded at $24.08, down $0.12, or 0.5% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 47,755
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 74,572
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 119,032

The average volume for Ciena has been 3.0 million shares per day over the past 30 days. Ciena has a market cap of $2.8 billion and is part of the technology sector and telecommunications industry. Shares are up 25.66% year-to-date as of the close of trading on Wednesday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. Currently, there are 12 analysts who rate Ciena a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings rates Ciena as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Ciena Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.